FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
By
Kathryn Wighton
June 26, 2026
Clinical Scorecard: FDA Approves New First-Line TNBC Regimen
At a Glance
Category Detail
Condition Triple-Negative Breast Cancer (TNBC) Key Mechanisms Combination of pembrolizumab with sacituzumab govitecan-hziy or chemotherapy Target Population Adult patients with unresectable locally advanced or metastatic TNBC expressing PD-L1 with a Combined Positive Score of 10 or greater Care Setting Oncology
Key Highlights
FDA approved pembrolizumab plus sacituzumab govitecan-hziy for first-line treatment of mTNBC. Approval based on phase 3 KEYNOTE-D19/ASCENT-04 trial with 443 patients. Pembrolizumab plus sacituzumab govitecan-hziy reduced risk of disease progression or death by 35%. Median progression-free survival was 11.2 months for the new regimen vs. 7.8 months for chemotherapy. Objective response rate was 61% with the new regimen compared to 55% with chemotherapy. Guideline-Based Recommendations
Diagnosis
Diagnosis of unresectable locally advanced or metastatic TNBC with PD-L1 expression. Management
Use pembrolizumab plus sacituzumab govitecan-hziy as a category 1 preferred first-line treatment. Monitoring & Follow-up
Monitor for common adverse reactions including decreased blood counts and gastrointestinal symptoms. Risks
Serious adverse reactions occurred in 38% of patients; fatal adverse reactions in 3.2%. Patient & Prescribing Data
Patients with recurrent unresectable or stage IV PD-L1-positive TNBC.
Combination therapy offers a new first-line treatment option with improved outcomes.
Clinical Best Practices
Consider patient eligibility based on PD-L1 expression and prior treatment history. Educate patients on potential adverse reactions and the importance of monitoring. Related Resources & Content
